The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Open accessAbstract
Thalidomide and its derivatives are powerful cancer therapeutics that are among the best-understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 ubiquitin ligase cereblon (CRBN) to commit target proteins for degradation by the ubiquitin-proteasome system. MGDs create novel recognition interfaces on the surface of the E3 ligase that engage in induced protein-protein interactions with neosubstrates. Molecular insight into their mechanism of action opens exciting opportunities to engage a plethora of targets through a specific recognition motif, the G-loop. Our analysis shows that current CRBN-based MGDs can in principle recognize over 2,500 proteins in the human proteome that contain a G-loop. We review recent advances in tuning the specificity between CRBN and its MGD-induced neosubstrates and deduce a set of simple rules that govern these interactions. We conclude that rational MGD design efforts will enable selective degradation of many more proteins, expanding this therapeutic modality to more disease areas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“together these results show that the targetable universe of proteins degradable by CRBN-recruiting MGs is not limited to POIs that contain the G-loop degron motif (4), or its structural mimic (11).”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [4]
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Highly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Self-citation
Research works printed but not linked: 2
- Bradner J., 2021, Molecular glues for intractable targets
- Fischer Lab, 2020, Fischer lab's proteomics database
Cited by
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
“CRBN has been proposed to recognize C-terminally cyclized glutamine or asparagine residues 88,89 , but the biological function remains to be fully elucidated 90,91 .”
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 210
“These neo-substrates show little sequence identity, but share a common structural degron, a β-hairpin containing a central glycine residue that mediates the interaction with CRBN 69 .”
Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition
Petzold, G., Gainza, P., Annunziato, S., Lamberto, I., Trenh, P., McAllister, L. A., DeMarco, B., Schwander, L., Bunker, R. D., Zlotosch, M., et al. (2025) · Science · doi:10.1126/science.adt6736 · Cited by 117
Self-citationContinuous evolution of compact protein degradation tags regulated by selective molecular glues
Mercer, J. A. M., DeCarlo, S. J., Burman, S. S. R., Sreekanth, V., Nelson, A. T., Hunkeler, M., Chen, P. J., Donovan, K. A., Kokkonda, P., Tiwari, P. K., et al. (2024) · Science · doi:10.1126/science.adk4422 · Cited by 86
“…may also be useful to provide compact degron tags that are compatible with the large diversity of other IMiD derivatives that have been developed (81), allowing IMiDs with especially desirable pharmacologic properties to be applied to targeted protein degradation or other molecular glue…”
Targeting protein–ligand neosurfaces with a generalizable deep learning tool
Marchand, A., Buckley, S., Schneuing, A., Pačesa, M., Elia, M., Gaínza, P., Elizarova, E., Neeser, R. M., Lee, P., Reymond, L., et al. (2025) · Nature · doi:10.1038/s41586-024-08435-4 · Cited by 98
“…expressive fingerprints from protein–ligand complexes opens up the possibility of rationally designing innovative drug modalities, such as on-demand cell-based therapies 10,19 , controllable biologics 22,24 and molecular glues, which has remained an outstanding challenge in drug development 13,14 .”
Self-citation
Metadata
- Authors
- Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B., & Thomä, N. H.
- Affiliations
- Monte Rosa Therapeutics AG, Basel, Switzerland;
- Sight and Life (CH)
- Friedrich Miescher Institute (CH)
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2024-01-23
- Volume
- 64
- Issue
- 1
- Pages
- 291-312
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W4385858012
- Cited by
- 178
- References
- 64
- Citations by year
- 2026: 53 · 2025: 92 · 2024: 31
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- molecular glues, thalidomide, cereblon, targeted protein degradation, E3 ubiquitin ligase, G-loop, ubiquitin-proteasome system, drug design, cancer therapeutics, protein-protein interaction
- MeSH terms
- Humans, Thalidomide, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-022123-104147
- The paper
- Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B., & Thomä, N. H. (2024). From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-022123-104147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.